Abstract
Objectives
Hypogonadism is defined as inadequate sex hormone production due to defects in the hypothalamic-pituitary-gonadal axis. In recent years, rare single gene defects have been identified in both hypergonadotropic hypogonadism (Hh), and hypogonadotropic hypogonadism (HH) cases with no chromosomal anomalies. The aim of the present study is to investigate the underlying molecular genetic etiology and the genotype-phenotype relationship of a series of patients with Hh and HH.
Methods
In total, 27 HH and six Hh cases were evaluated. Clinical and laboratory features are extracted from patients’ hospital files. Whole exome sequencing (WES) analysis was performed.
Results
A total of 27 HH cases (15 female) (mean age: 15.8 ± 2.7 years) and six Hh patients (six females) (mean age: 14.9 ± 1.2 years) were included. In molecular genetic analysis, a pathogenic/likely pathogenic variant was identified in five (two patients from the same family) of 27 HH cases (two novel) and three of the six Hh. In HH group variants (pathogenic, likely pathogenic and variant of uncertain significance) were identified in KISS1R (n=2), PROK2 (n=1), FGFR1 (n=1), HS6ST1 (n=1), GNRH1 (n=1) genes. In the Hh group, splice-site mutations were detected in DCAF17 (n=1) and MCM9 (n=2) genes.
Conclusions
HH and Hh cases are genetically heterogeneous diseases due to oligogenic inheritance, incomplete penetrance, and variable expressivity. We found rare variants in CHH related genes in half of our HH cases, whereas they classified as pathogenic/likely pathogenic according to ACMG criteria in only about 15% of HH cases. Using advanced genetic analysis methods such as whole-genome sequencing and long-read sequencing may increase the mutation detection rate, which should always be associated with and expert genetic counseling to interpret the data.
Acknowledgments
The authors wish to thank the individuals and their families for their participation in this study, as well as the clinicians for providing patient samples and information.
Research funding: None declared.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Bhasin, S, Basaria, B. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metabol 2011;25:251–70. https://doi.org/10.1016/j.beem.2010.12.002.Search in Google Scholar
2. Salonia, A, Rastrelli, G, Hackett, G, Seminara, B, Huhtaniemi, I, Rey, R, et al.. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers 2019;5:38. https://doi.org/10.1038/s41572-019-0087-y.Search in Google Scholar
3. Ross, A, Bhasin, S. Hypogonadism: its prevalence and diagnosis. Urol Clin 2016;43:163–76. https://doi.org/10.1016/j.ucl.2016.01.002.Search in Google Scholar
4. Jolly, A, Bayram, Y, Turan, S, Aycan, Z, Tos, T, Abalı, ZY, et al.. Exome sequencing of a primary ovarian insufficiency cohort reveals common molecular etiologies for a spectrum of disease. J Clin Endocrinol Metab 2019;104:3049–67. https://doi.org/10.1210/jc.2019-00248.Search in Google Scholar
5. Topaloğlu, AK. Update on the genetics of idiopathic hypogonadotropic hypogonadism. J Clin Res Pediatr Endocrinol 2017;9:113–22. https://doi.org/10.4274/jcrpe.2017.S010.Search in Google Scholar
6. Laitinen, EM, Vaaralahti, K, Tommiska, J, Eklund, E, Tervaniemi, M, Valanne, L, et al.. Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. Orphanet J Rare Dis 2011;6:41. https://doi.org/10.1186/1750-1172-6-41.Search in Google Scholar
7. Nair, S, Jadhav, S, Lila, A, Jagtap, V, Bukan, A, Pandit, R, et al.. Spectrum of phenotype and genotype of congenital isolated hypogonadotropic hypogonadism in Asian Indians. Clin Endocrinol (Oxf) 2016;85:100–9. https://doi.org/10.1111/cen.13009.Search in Google Scholar
8. Quinton, R, Duke, VM, Robertson, A, Kirk, JM, Matfin, G, de Zoysa, PA, et al.. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin Endocrinol 2001;55:163–74. https://doi.org/10.1046/j.1365-2265.2001.01277.x.Search in Google Scholar
9. Balasubramanian, R, Crowley, WFJr. Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network. Mol Cell Endocrinol 2011;346:4–12. https://doi.org/10.1016/j.mce.2011.07.012.Search in Google Scholar
10. Crowley, WFJr, Pitteloud, N, Seminara, S. New genes controlling human reproduction and how you find them. Trans Am Clin Climatol Assoc 2008;119:29–37.Search in Google Scholar
11. Maione, L, Dwyer, AA, Francou, B, Guiochon-Mantel, A, Binart, N, Bouligand, J, et al.. Genetics IN endocrinology: genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. Eur J Endocrinol 2018;178:R55–80. https://doi.org/10.1530/eje-17-0749.Search in Google Scholar
12. Rehm, HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet 2013;14:295–300. https://doi.org/10.1038/nrg3463.Search in Google Scholar
13. Binder, G, Schweizer, R, Blumenstock, G, Braun, R. Inhibin B plus LH vs GnRH agonist test for distinguishing constitutional delay of growth and puberty from isolated hypogonadotropic hypogonadism in boys. Clin Endocrinol (Oxf) 2015;82:100–5. https://doi.org/10.1111/cen.12613.Search in Google Scholar
14. Aoyama, K, Mizuno, H, Tanaka, T, Togawa, T, Negishi, Y, Ohashi, K, et al.. Molecular genetic and clinical delineation of 22 patients with congenital hypogonadotropic hypogonadism. J Pediatr Endocrinol Metab 2017;30:1111–8. https://doi.org/10.1515/jpem-2017-0035.Search in Google Scholar
15. Richards, S, Aziz, N, Bale, S, Bick, D, Das, S, Gastier-Foster, J, et al.. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med 2015;17:405–24. https://doi.org/10.1038/gim.2015.30.Search in Google Scholar
16. Kurnaz, E, Türkyılmaz, A, Yaralı, O, Demir, B, Çayır, A. A novel DCAF17 homozygous mutation in a girl with Woodhouse–Sakati syndrome and review of the current literature. J Pediatr Endocrinol Metab 2019;32:1287–93. https://doi.org/10.1515/jpem-2019-0173.Search in Google Scholar
17. Wood-Trageser, MA, Gurbuz, F, Yatsenko, SA, Jefries, EP, Kotan, LD, Surti, U, et al.. MCM9 mutations are associated with ovarian failure, short stature, and chromosomal instability. Am J Hum Genet 2014;95:754–62. https://doi.org/10.1016/j.ajhg.2014.11.002.Search in Google Scholar
18. Miraoui, H, Dwyer, AA, Sykiotis, GP, Plummer, L, Chung, W, Feng, B, et al.. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet 2013;92:725–43. https://doi.org/10.1016/j.ajhg.2013.04.008.Search in Google Scholar
19. Zhu, J, Choa, RE, Guo, MH, Plummer, L, Buck, C, Palmert, MR, et al.. A shared genetic basis for self-limited delayed puberty and idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2015;100:E646–54. https://doi.org/10.1210/jc.2015-1080.Search in Google Scholar
20. Chan, YM, de Guillebon, A, Lang-Muritano, M, Plummer, L, Cerrato, F, Tsiaras, S, et al.. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2009;106:11703–8. https://doi.org/10.1073/pnas.0903449106.Search in Google Scholar
21. Cangiano, B, Swee, DS, Quinton, R, Bonomi, M. Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. Hum Genet 2020;140:77–111. https://doi.org/10.1007/s00439-020-02147-1.Search in Google Scholar
22. Messina, A, Ferraris, N, Wray, S, Cagnoni, G, Donohue, DE, Casoni, F, et al.. Dysregulation of Semaphorin7A/ß1-integrin signaling leads to defective GnRH-1 cell migration, abnormal gonadal development and altered fertility. Hum Mol Genet 2011;20:4759–74. https://doi.org/10.1093/hmg/ddr403.Search in Google Scholar
23. Young, J, Metay, C, Bouligand, J, Tou, B, Francou, B, Maione, L, et al.. SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Hum Reprod 2012;27:1460–5. https://doi.org/10.1093/humrep/des022.Search in Google Scholar
24. Hanchate, NK, Giacobini, P, Lhuillier, P, Parkash, J, Espy, C, Fouveaut, C, et al.. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet 2012;8:e1002896. https://doi.org/10.1371/journal.pgen.1002896.Search in Google Scholar
25. Sagi, SV, Joshi, H, Whiles, E, Hikmat, M, Puthi, VR, MacDougall, J, et al.. Normosmic idiopathic hypogonadotropic hypogonadism due to a novel GNRH1 variant in two siblings. Endocrinol Diabetes Metab Case Rep 2020;2020:19–0145. https://doi.org/10.1530/edm-19-0145.Search in Google Scholar
26. Amato, LGL, Montenegro, LR, Lerario, AM, Jorge, AAL, Guerra Junior, G, Schnoll, C, et al.. New genetic findings in a large cohort of congenital hypogonadotropic hypogonadism. Eur J Endocrinol 2019;181:103–19. https://doi.org/10.1530/eje-18-0764.Search in Google Scholar
27. Bouligand, J, Ghervan, C, Tello, JA, Brailly-Tabard, S, Salenave, S, Chanson, P, et al.. Isolated familial hypogonadotropic hypogonadism and a GNRH1 mutation. N Engl J Med 2009;360:2742–8. https://doi.org/10.1056/nejmoa0900136.Search in Google Scholar
28. Tornberg, J, Sykiotis, GP, Keefe, K, Plummer, L, Hoang, X, Hall, JE, et al.. Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism. Proc Natl Acad Sci USA 2011;108:11524–9. https://doi.org/10.1073/pnas.1102284108.Search in Google Scholar
29. Costa-Barbosa, FA, Balasubramanian, R, Keefe, KW, Shaw, ND, Al-Tassan, N, Plummer, L, et al.. Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes. J Clin Endocrinol Metab 2013;98:E943–53. https://doi.org/10.1210/jc.2012-4116.Search in Google Scholar
30. Gach, A, Pinkier, I, Szarras-Czapnik, M, Sakowicz, A, Jakubowski, L. Expanding the mutational spectrum of monogenic hypogonadotropic hypogonadism: novel mutations in ANOS1 and FGFR1 genes. Reprod Biol Endocrinol 2020;18:8. https://doi.org/10.1186/s12958-020-0568-6.Search in Google Scholar
31. Demirbilek, H, Ozbek, MN, Demir, K, Kotan, LD, Cesur, Y, Dogan, M, et al.. Normosmic idiopathic hypogonadotropic hypogonadism due to a novel homozygous nonsense c.C969A (p.Y323X) mutation in the KISS1R gene in three unrelated families. Clin Endocrinol (Oxf) 2015;82:429–38. https://doi.org/10.1111/cen.12618.Search in Google Scholar
32. Cao, Y, Li, Z, Jiang, W, Ling, Y, Kuang, H. Reproductive functions of kisspeptin/KISS1R systems in the periphery. Reprod Biol Endocrinol 2019;17:65. https://doi.org/10.1186/s12958-019-0511-x.Search in Google Scholar
33. Teles, MG, Bianco, SDC, Brito, VN, Trarbach, EB, Kuohung, W, Xu, S, et al.. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008;358:709–15. https://doi.org/10.1056/nejmoa073443.Search in Google Scholar
34. Li, C, Scott, DA, Hatch, E, Tian, X, Mansour, SL. Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development. Development 2007;134:167–76. https://doi.org/10.1242/dev.02701.Search in Google Scholar
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2020-0590).
© 2021 Walter de Gruyter GmbH, Berlin/Boston
